Publication date: Dec 01, 2024
Literature on the safety of remdesivir in hospitalized COVID-19 patients with severe renal impairment is limited. We aimed to investigate the safety and effectiveness of remdesivir in this population. We conducted a retrospective cohort study of adult hospitalized COVID-19 patients who received remdesivir between April 2022 and October 2022. Outcomes were compared between estimated glomerular filtration rate (eGFR)
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | effectiveness |
| disease | MESH | COVID-19 |
| disease | VO | population |
| disease | MESH | Acute Kidney Injury |
| drug | DRUGBANK | Adenosine phosphate |
| drug | DRUGBANK | L-Alanine |
| disease | MESH | Bradycardia |
| disease | MESH | Renal Insufficiency |
Original Article
(Visited 2 times, 1 visits today)